LYEL
Lyell Immunopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.37
+0.35%Next report
Analyst consensus
- Next report date
- Nov 10, 2026
- EPS estimate
- -$2.06
- Revenue estimate
- $3.8K
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$1.92
- EPS estimate
- -$1.90
- Revenue actual
- $4.0K
- Revenue estimate
- $3.6K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -46.3%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $41
- PT range
- $34 – $45
- Analysts
- 5
5 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 10, 2026